Jana Populova

Jana Populova

Auto-generated profile, based on publicly available information

Jana Populova

Institute of Physiology, Second Faculty of Medicine, Charles University, Prague, Czech Republic Epilepsy Research Centre Prague (EpiReC), Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MŘMonika ŘehořOvá
Monika ŘehořOvá
JRJana Thao Rozlivková
Jana Thao Rozlivková
JPJana Populová
Jana Populová
NPNatálie Procházková
Natálie Procházková
COCarl Václav Lím Olson
Carl Václav Lím Olson
ONOndřEj Novák
OndřEj Novák
Objective: Focal cortical dysplasia type II (FCD II) is a leading cause of drug-resistant focal epilepsy, yet how its lesional circuits behave and change over time in vivo has not been directly observed. Methods: We used a mouse model of FCD II carrying the patient-derived gain-of-function mTOR p.L2427P variant introduced by in utero electroporation. Through a chronic cranial window over the lesion, we performed repeated in vivo two-photon calcium imaging of identified dysmorphic neurons, pyramidal cells, and VIP interneurons at defined time points, combined with video-EEG monitoring, to determine seizure status and relate cellular activity to interictal discharges. Results: The lesion was not static in adulthood. Dysplastic cortex expanded progressively. This expansion occurred without the tenascin R/C accumulation reported in human FCD II, and was partly explained by continued somatic growth of dysmorphic neurons. Dysmorphic neurons were generally hypoactive; in seizing mice, both dysmorphic and pyramidal cell activity progressively declined, whereas VIP interneuron activity increased slightly in non-seizing animals. In non-seizing lesional cortex, neurons were reliably recruited immediately before interictal discharges. By late disease stages, pre-discharge recruitment had weakened to the point that lesional layer 2/3 neurons were no more active before discharges than expected by chance. Significance: These findings recast FCD II as a lesion that continues to remodel structurally and functionally throughout adulthood, and does so most markedly in animals with seizures. Growth, a cell-type-specific shift in spontaneous activity, and a progressive loss of the lesion’s temporal lead over interictal discharges together suggest that FCD II is a dynamically evolving lesion whose relationship to epileptiform activity changes over time. If the lesion progressively loses its generative role, the window in which removing it can arrest the disease is finite, consistent with clinical evidence favoring earlier surgery. Key points: The same neurons inside an FCD II lesion were imaged in vivo across epileptogenesis Dysplastic cortex expanded over weeks, tending to be larger in seizing mice Expansion coincided with dysmorphic neuron growth without bulk tenascin R/C increase In seizing mice, dysmorphic and pyramidal neurons became progressively less active Pre-discharge neuronal recruitment in non-seizing mice was absent in seizing mice

20 October 2025 in bioRxiv
Verified
Preprint
Open access
NPN Procházková
N Procházková
COCvl Olson
Cvl Olson
NSN Shariati
N Shariati
MRMt Rozlivková
Mt Rozlivková
JPJ Populová
J Populová
ONO Novák
O Novák
Focal cortical dysplasia (FCD) is a common malformation of cortical development and a major cause of early-onset, drug-resistant epilepsy. FCD type II is defined by abnormal lamination, altered cellular composition, and pathological cells, notably dysmorphic neurons (DNs) and balloon cells. DNs are thought to drive epileptogenicity through both cell-autonomous and non-cell-autonomous mechanisms, the latter including not only aberrant connectivity but also indirect modulation of excitability in local cell populations. We performed a multiscale structural and morphological analysis to elucidate the basis of FCD epileptogenicity and the impact of somatic mTOR mutations during brain development. Using a mouse model of FCD type II, we show that lesions in frontal and motor cortical regions are the strongest predictors of spontaneous seizure occurrence. This localization-dependent epileptogenicity offers an experimental explanation for the higher clinical epileptogenicity of frontal FCDs and suggests that posterior lesions may remain silent—an open question in human pathology. In our model, FCD tissue displayed considerable expansion, with cortical thickness up to ∼20% in seizure-bearing animals. This expansion coincided with an overall ∼40% reduction in neuronal density, consistent with tissue hypertrophy. DN density did not differ between seizure and non-seizure animals, challenging the notion that higher DN load directly predicts epileptogenesis. At the microscopic level, we describe DN axonal pathologies, including giant varicosities. In the cortex, these appeared as vesicle-filled boutons, whereas along callosal axons they were frequent but largely empty. Bouton density was markedly reduced in FCD cortex. Together, these findings leave the net synaptic effect of dysmorphic neurons unresolved, challenging the assumption that axonal hypertrophy translates into increased excitatory drive. While morphological abnormalities in FCD type II are well documented, their functional consequences remain incompletely understood. Here, we used macro- and microscopic structural features of FCDII to assess seizure susceptibility, providing new insights into epileptogenesis.

21 May 2026 in bioRxiv
Verified
Preprint
Open access
COC.V.L. Olson
C.V.L. Olson
NSN. Shariati
N. Shariati
NPN. Procházková
N. Procházková
KČK. Čížek
K. Čížek
MŘM. ŘehořOvá
M. ŘehořOvá
ONO. Novák
O. Novák
Summary: Objective: Focal cortical dysplasia (FCD) type II is a common cause of pediatric drug-resistant epilepsy with no disease-modifying treatment. It arises from somatic mutations in the mTOR pathway that produce a mosaic population of mTOR-hyperactive dysmorphic neurons (DNs) with a senescence phenotype. A recent report showed that oral dasatinib– quercetin (DQ), both putative senolytics, selectively eliminates these neurons and abolishes seizures in an Mtor p.S2215F model. However, this has not been tested in a second FCD model and neuron loss was shown only by cross-sectional histology. Methods: Using chronic cranial windows and longitudinal in vivo two-photon imaging, we tracked genetically labeled neurons over eight weeks. In a mosaic MTOR p.L2427P FCD model on a C57BL/6J background, we combined imaging with continuous video-EEG, immunohistochemistry (IHC), and LC–MS/MS pharmacokinetics in 47 mice. Seizure and pharmacokinetic sampling were extended to a smaller Swiss/CD1 cohort, the strain used previously. Results: Imaging revealed progressive loss of mTOR mut (16.7%) and non-mTOR mut (13.1%) neurons, with minimal loss in unmatched non-FCD controls. In IHC, lesions contained β-galactosidase-positive (B-Gal + ) cells, but oral DQ showed no evidence of eliminating DNs or reducing seizure frequency, duration, or burden; seizures also persisted in CD1 mice. B-Gal + cells tended to be less dense after DQ, but not significantly after correction. These data are more consistent with a senomorphic than a senolytic effect. Brain dasatinib (median 8.5 nM) exceeded its Src/ABL IC 50 , whereas quercetin (median 12 nM) was nearly two orders of magnitude below its BCL-XL affinity. Significance: Longitudinal tracking of single neurons shows progressive loss of labeled neurons in an FCD model, whereas the reported senolytic and antiseizure effects of DQ were not reproduced. DQ should not be assumed to act as a senolytic across FCD models, strains, or MTOR variants. Dependence on strain, mutation, or brain exposure bears on clinical translation. Key Points Longitudinal in vivo two-photon imaging showed progressive loss of mTOR-mutant neurons in an FCD type II mouse model Oral dasatinib–quercetin treatment did not eliminate dysmorphic neurons or reduce seizures in C57BL/6J mice; seizures persisted in CD1 mice Dasatinib–quercetin did not eliminate neurons or abolish seizures in an MTOR p.L2427P FCD model, so its efficacy may not generalize